DSDarci R. Smith

Darci R. Smith

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Darci R. Smith has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Lisa E. Hensley

    Zoonotic and Emerging Disease Research Unit, United States Department of Agriculture, Agriculture Research Service (USDA-ARS), Manhattan, KS, USA

    3 shared publications
  • Anna N. Honko

    Department of Microbiology and National Emerging Infectious Diseases Laboratories, Boston University School of Medicine, Boston, Massachusetts 02118, United States

    2 shared publications
  • Joshua Shamblin

    U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA

    2 shared publications
  • Ashley Keeney

    U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA

    1 shared publication
  • Brian H. Bird

    Centers for Disease Control and Prevention, Viral Special Pathogens Branch, Atlanta, Georgia, USA

    1 shared publication
  • Brian M. Friedrich

    United States Army Medical Research Institute of Infectious Diseases, Division of Virology, 1425 Porter Street, Frederick, MD 21702, USA

    1 shared publication

Latest Publications

  • Open Access

    Potential Vaccines and Post-Exposure Treatments for Filovirus Infections

    by Brian M. Friedrich, John C. Trefry, Julia E. Biggins, Lisa E. Hensley, Anna N. Honko, Darci R. Smith, Gene G. Olinger

    Viruses of the family Filoviridae represent significant health risks as emerging infectious diseases as well as potentially engineered biothreats. While many research efforts have been published offering possibilities toward the mitigation of filoviral infection, there remain no sanctioned therapeutic or vaccine strategies. Current progress in the development of filovirus therapeutics and vaccines is outlined herein with respect to their current level of testing, evaluation, and proximity toward human implementation, specifically with regard to human clinical trials, nonhuman primate studies, small animal studies, and in vitro development. Contemporary methods of supportive care and previous treatment approaches for human patients are also discussed.


  • Development of a Novel Nonhuman Primate Model for Rift Valley Fever

    by Darci R. Smith, Brian H. Bird, Bridget Lewis, Sara C. Johnston, Sarah McCarthy, Ashley Keeney, Miriam Botto, Ginger Donnelly, Joshua Shamblin, César G. Albariño, et al.

    Rift Valley fever (RVF) virus (RVFV) can cause severe human disease characterized by either acute-onset hepatitis, delayed-onset encephalitis, retinitis and blindness, or a hemorrhagic syndrome. The existing nonhuman primate (NHP) model for RVF utilizes an intravenous (i.v.) exposure route in rhesus macaques (Macaca mulatta). Severe disease in these animals is infrequent, and large cohorts are needed to observe significant morbidity and mortality. To overcome these drawbacks, we evaluated the infectivity and pathogenicity of RVFV in the common marmoset (Callithrix jacchus) by i.v., subcutaneous (s.c.), and intranasal exposure routes to more closely mimic natural exposure. Marmosets were more susceptible to RVFV than rhesus macaques and experienced higher rates of morbidity, mortality, and viremia and marked aberrations in hematological and chemistry values. An overwhelming infection of hepatocytes was a major consequence of infection of marmosets by the i.v. and s.c. exposure routes. Additionally, these animals displayed signs of hemorrhagic manifestations and neurological impairment. Based on our results, the common marmoset model more closely resembles severe human RVF disease and is therefore an ideal model for the evaluation of potential vaccines and therapeutics.


  • The pathogenesis of Rift Valley fever virus in the mouse model

    by Darci R. Smith, Keith E. Steele, Joshua Shamblin, Anna Honko, Joshua Johnson, Christopher Reed, Maureen Kennedy, Jennifer L. Chapman, Lisa E. Hensley


  • Development of Field-Based Real-Time Reverse Transcription–Polymerase Chain Reaction Assays for Detection of Chikungunya and O’nyong-nyong Viruses in Mosquitoes

    by Darci R. Smith, John S. Lee, Jordan Jahrling, David A. Kulesh, Michael J. Turell, Jennifer L. Groebner, Monica L. O’guinn

    Chikungunya (CHIK) and O’nyong-nyong (ONN) are important emerging arthropod-borne diseases. Molecular diagnosis of these two viruses in mosquitoes has not been evaluated, and the effects of extraneous mosquito tissue on assay performance have not been tested. Additionally, no real-time reverse transcription–polymerase chain reaction (RT-PCR) assay exists for detecting ONN virus (ONNV) RNA. We describe the development of sensitive and specific real-time RT-PCR assays for detecting CHIK and ONN viral RNA in mosquitoes, which have application for field use. In addition, we compared three methods for primer/probe design for assay development by evaluating their sensitivity and specificity. This comparison resulted in development of virus-specific assays that could detect less than one plaque-forming unit equivalent of each of the viruses in mosquitoes. The use of these assays will aid in arthropod-borne disease surveillance and in the control of the associated diseases.